Systematic review on evidence of the effectiveness of cholesterol-lowering drugs
- 599 Downloads
Coronary heart disease (CHD) is the leading cause of mortality worldwide. With increasingly urbanized lifestyles in developing countries and the aging populations, the major risk factors for CHD such as obesity, diabetes mellitus, and hypercholesterolemia are likely to increase in the future. In the current report, we reviewed the evidence on the effect of cholesterol lowering using pharmacological agents.
A PubMed/Medline systematic search was performed over the past 12 years (1998–2009 inclusive) and relevant papers written in the English language were selected. We used key phrases including, “risk factors for hypercholesterolemia,” “management of hypercholesterolemia,” “guidelines for management of hypercholesterolemia,” and “pharmacological management of hypercholesterolemia.”
There were a total of over 3500 reports. We selected key publications on the effect of cholesterol lowering using different pharmacological agents.
Several options exist with regards to pharmacological management of hypercholesterolemia. There is a substantial body of evidence to support the effect of a population shift towards a favorable risk profile, which has huge potential in reducing the burden of CHD globally.
Keywordscardiovascular disease cholesterol-lowering drugs coronary heart disease hypercholesterolemia risk
Unable to display preview. Download preview PDF.
- 1.DOH web site. Coronary heart disease. Policy and guidance. London: Department of Health. Available at: http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/CoronaryHeartDisease/fs/en. Last accessed February 24, 2010.
- 4.American Heart Association, National Heart, Lung, and Blood Institute. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation. 1990;81:1721–1733.Google Scholar
- 6.Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.Google Scholar
- 7.Wood D. Joint British Societies guidelines on prevention of cardiovascular disease in clinical practice. JBS-2. Heart. 2005;91(suppl. V):1–2.Google Scholar
- 19.Olsson AG, Eriksson M, Johnson O, et al. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study. Clin Ther. 2003;25:119–138.PubMedCrossRefGoogle Scholar
- 23.Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin induced myopathy — a genomewide study. N Engl J Med. 2008;8:789–799.Google Scholar
- 32.Rubins, Bloomfield H, Davenport J, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103:2828–2833.Google Scholar
- 33.[No authors listed]. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the BIP study. Circulation. 2000;102:21–27.Google Scholar
- 55.Hooper L, Thompson RL, Harrison RA, et al.Omega 3 fatty acids for prevention and treatment of CVD. Cochrane Database Syst Rev. 2004;(4):CD003177.Google Scholar
- 58.Lee IM, Cook NR, Gaziana JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Womens Health Study: a randomised controlled trial. JAMA. 2002;288:322–333.Google Scholar
- 69.Taylor AJ, Sullenberger LE, Lee HJ. Arterial Biology for the Investigation of the Treatment Effects of Cholesterol (ARBITOR-2): a double blind placebo controlled study of extended release niacin in atherosclerosis progression in secondary prevention. Patients treated with statins. Circulation. 2004;110:2–7.CrossRefGoogle Scholar
- 73.Goldberg AC, Sapre A, Liu L, Capece R, Mitchel YB. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79:620–629.PubMedCrossRefGoogle Scholar
- 83.Stamler J, Wentworth D, Neaton JD. Is the relation between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823–2828.PubMedCrossRefGoogle Scholar
- 86.Assman G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow up at 8th years. Eur Heart J. 1998;19(suppl. A):A2–A11.Google Scholar
- 91.Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158.PubMedCrossRefGoogle Scholar
- 94.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.Google Scholar
- 97.James H, O’Keefe Jr. Optimal LDL is 50-70 mg/dL. Lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:11.Google Scholar
- 99.NHS web site. The information centre for health and social care. Prescriptions dispensed in the community 1996-2006 [NS]. Department of Health. Available at: http://www.ic.nhs.uk/statisticsand-data-collections/primary-care/prescriptions/prescriptions-dispensed-in-the-community-1996-2006-%5Bns%5D. Last accessed February 24, 2010.
- 100.NICE web site. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Available at: http://guidance.nice.org.uk/CG67. Last accessed February 24, 2010.
- 104.The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative research group. The antihypertensive and lipid lowering treatment for prevention of heart attack trial: major outcomes in moderately hypercholesterolemic hypertensive patients randomised to pravastatin or usual care. ALLHAT-LLT. JAMA. 2002;288:2998–3007.CrossRefGoogle Scholar
- 109.Spriston K, Primatesta P, eds. Risk Factors for Cardiovascular Disease. Health Survey for England 2003. Vol. 2. London: The Stationery Office; 2004.Google Scholar